×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Intellia ups the ante in HAE dosing battle, showcasing durability of one-and-done option
Fierce Biotech
The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks.
8 hours ago
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial
The Business Journals
The gene-editing company shared new data this weekend that it says will support a late-stage clinical trial of its hereditary angioedema...
8 hours ago
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an ...
GlobeNewswire
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure...
8 hours ago
Intellia (NTLA) Up on Positive Data Updates From HAE Study
Yahoo News Singapore
Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary...
2 days ago
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial
Clinical Trials Arena
Intellia Therapeutic's NTLA-2001 is the first in vivo CRISPR candidate to make late-stage trials.
2 months ago
Intellia Earnings: Novel Gene Editing Pipeline Advances; Shares Attractive for Long-Term Investors
Morningstar
Intellia Therapeutics' relatively early-stage gene editing pipeline continued to make progress in the first quarter.
3 weeks ago
Better Cathie Wood Stock: Moderna vs. Intellia
The Motley Fool
This week, Wood has been adding to her positions in biotech companies Moderna (MRNA -3.45%) and Intellia Therapeutics (NTLA -4.62%). Moderna,...
2 months ago
Chardan Capital Analysts Increase Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Defense World
Read Chardan Capital Analysts Increase Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA) at Defense World.
1 day ago
Intellia propels into 2024 with CRISPR pipeline updates
Pharmaceutical Technology
The Massachusetts-headquartered company announced its 2024 aim to complete patient enrolment for studies evaluating NTLA-2001 and NTLA-2002.
4 months ago
Intellia expands gene editing with $45m Rewrite buy - BioProcess Insider
BioProcess International
The deal will see Intellia Therapeutics will add Rewrite Therapeutics' DNA writing platform and expand its CRISPR functionality.
2 months ago